988 related articles for article (PubMed ID: 22763451)
1. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice.
Tsai PT; Hull C; Chu Y; Greene-Colozzi E; Sadowski AR; Leech JM; Steinberg J; Crawley JN; Regehr WG; Sahin M
Nature; 2012 Aug; 488(7413):647-51. PubMed ID: 22763451
[TBL] [Abstract][Full Text] [Related]
2. Sensitive Periods for Cerebellar-Mediated Autistic-like Behaviors.
Tsai PT; Rudolph S; Guo C; Ellegood J; Gibson JM; Schaeffer SM; Mogavero J; Lerch JP; Regehr W; Sahin M
Cell Rep; 2018 Oct; 25(2):357-367.e4. PubMed ID: 30304677
[TBL] [Abstract][Full Text] [Related]
3. Purkinje cells derived from TSC patients display hypoexcitability and synaptic deficits associated with reduced FMRP levels and reversed by rapamycin.
Sundberg M; Tochitsky I; Buchholz DE; Winden K; Kujala V; Kapur K; Cataltepe D; Turner D; Han MJ; Woolf CJ; Hatten ME; Sahin M
Mol Psychiatry; 2018 Nov; 23(11):2167-2183. PubMed ID: 29449635
[TBL] [Abstract][Full Text] [Related]
4. Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex.
Reith RM; McKenna J; Wu H; Hashmi SS; Cho SH; Dash PK; Gambello MJ
Neurobiol Dis; 2013 Mar; 51():93-103. PubMed ID: 23123587
[TBL] [Abstract][Full Text] [Related]
5. Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration.
Reith RM; Way S; McKenna J; Haines K; Gambello MJ
Neurobiol Dis; 2011 Jul; 43(1):113-22. PubMed ID: 21419848
[TBL] [Abstract][Full Text] [Related]
6. Tsc2 mutation rather than Tsc1 mutation dominantly causes a social deficit in a mouse model of tuberous sclerosis complex.
Kashii H; Kasai S; Sato A; Hagino Y; Nishito Y; Kobayashi T; Hino O; Mizuguchi M; Ikeda K
Hum Genomics; 2023 Feb; 17(1):4. PubMed ID: 36732866
[TBL] [Abstract][Full Text] [Related]
7. Cerebellar Development and Autism Spectrum Disorder in Tuberous Sclerosis Complex.
Sundberg M; Sahin M
J Child Neurol; 2015 Dec; 30(14):1954-62. PubMed ID: 26303409
[TBL] [Abstract][Full Text] [Related]
8. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
[TBL] [Abstract][Full Text] [Related]
9. A brain proteomic investigation of rapamycin effects in the
Wesseling H; Elgersma Y; Bahn S
Mol Autism; 2017; 8():41. PubMed ID: 28775826
[TBL] [Abstract][Full Text] [Related]
10. Behavioural and EEG effects of chronic rapamycin treatment in a mouse model of tuberous sclerosis complex.
Cambiaghi M; Cursi M; Magri L; Castoldi V; Comi G; Minicucci F; Galli R; Leocani L
Neuropharmacology; 2013 Apr; 67():1-7. PubMed ID: 23159330
[TBL] [Abstract][Full Text] [Related]
11. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis.
Ehninger D; Han S; Shilyansky C; Zhou Y; Li W; Kwiatkowski DJ; Ramesh V; Silva AJ
Nat Med; 2008 Aug; 14(8):843-8. PubMed ID: 18568033
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitor reverses autistic-like social deficit behaviours in adult rats with both Tsc2 haploinsufficiency and developmental status epilepticus.
Schneider M; de Vries PJ; Schönig K; Rößner V; Waltereit R
Eur Arch Psychiatry Clin Neurosci; 2017 Aug; 267(5):455-463. PubMed ID: 27263037
[TBL] [Abstract][Full Text] [Related]
13. Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice.
Feliciano DM; Su T; Lopez J; Platel JC; Bordey A
J Clin Invest; 2011 Apr; 121(4):1596-607. PubMed ID: 21403402
[TBL] [Abstract][Full Text] [Related]
14. Altered ultrasonic vocalizations in a tuberous sclerosis mouse model of autism.
Young DM; Schenk AK; Yang SB; Jan YN; Jan LY
Proc Natl Acad Sci U S A; 2010 Jun; 107(24):11074-9. PubMed ID: 20534473
[TBL] [Abstract][Full Text] [Related]
15. Autistic-Like Traits and Cerebellar Dysfunction in Purkinje Cell PTEN Knock-Out Mice.
Cupolillo D; Hoxha E; Faralli A; De Luca A; Rossi F; Tempia F; Carulli D
Neuropsychopharmacology; 2016 May; 41(6):1457-66. PubMed ID: 26538449
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.
Ehninger D; Silva AJ
Trends Mol Med; 2011 Feb; 17(2):78-87. PubMed ID: 21115397
[TBL] [Abstract][Full Text] [Related]
17. Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
Di Nardo A; Kramvis I; Cho N; Sadowski A; Meikle L; Kwiatkowski DJ; Sahin M
J Neurosci; 2009 May; 29(18):5926-37. PubMed ID: 19420259
[TBL] [Abstract][Full Text] [Related]
18. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex.
Sato A; Kasai S; Kobayashi T; Takamatsu Y; Hino O; Ikeda K; Mizuguchi M
Nat Commun; 2012; 3():1292. PubMed ID: 23250422
[TBL] [Abstract][Full Text] [Related]
20. Restoration of Normal Cerebral Oxygen Consumption with Rapamycin Treatment in a Rat Model of Autism-Tuberous Sclerosis.
Chi OZ; Wu CC; Liu X; Rah KH; Jacinto E; Weiss HR
Neuromolecular Med; 2015 Sep; 17(3):305-13. PubMed ID: 26048361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
